Autoreactive B cells in SLE have long been considered therapeutic targets, and CAR-T cell strategies targeting CD19 may achieve more effective and durable B-cell depletion, particularly in inflamed tissues affected by SLE [30,171]. This evidence concerns the gene CD19 and systemic lupus erythematosus.